Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05760742
Other study ID # STUDY00004940
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 10, 2023
Est. completion date August 18, 2023

Study information

Verified date September 2023
Source Microphyt
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this investigation is to examine the effects of consuming a new dietary microalgae based supplement vs. placebo on neuromuscular function, energy utilization, soreness, perceptual wellness, swelling, and markers of muscle damage and inflammation in healthy young men before and after an acute exercise-induced muscle damage protocol (downhill running), and influence on endurance capacity after prolonged consumption.


Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date August 18, 2023
Est. primary completion date August 1, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Male participants - Healthy as assessed by Medical and activity history questionnaire (MHQ) - Recreationally active according to American College of Sports Medicine guidelines - Able to provide written and dated informed consent to participate in the study Exclusion Criteria: - Untrained - Any response of "yes" on the PAR-Q+ - Physical limitations preventing running, countermovement jump, and strength (peak isometric torque and peak isokinetic torque) assessments

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
MicAlgae
2 months of supplementation with an innovative microalgae based ingredient
Placebo
2 months of supplementation with a placebo (Maltodextrin)

Locations

Country Name City State
United States University of Central Florida Orlando Florida

Sponsors (2)

Lead Sponsor Collaborator
Microphyt University of Central Florida

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuromuscular function isokinetic peak torque in Newton per meter (N/m) From 0 to week 4
Secondary Energy utilization (Oxygen consumption - VO2) Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis From 0 to week 4
Secondary Energy utilization (Oxygen consumption - VO2) Running economy during a 5-minute run at 80% of the speed at VO2max with gaz exchange analyzis From 0 to week 8
Secondary Isokinetic neuromuscular function peak torque in Newton per meter (N/m) From 0 to week 8
Secondary Isometric neuromuscular function peak torque in Newton per meter (N/m) From 0 to week 8
Secondary Endurance capacity Maximal oxygen consumption (VO2max) determined during graded exercise test From 0 to week 4
Secondary Endurance capacity Maximal oxygen consumption (VO2max) determined during graded exercise test From 0 to week 8
Secondary Soreness and perceptual wellness Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol From 0 to week 4
Secondary Soreness and perceptual wellness Evaluated using using a 100-point numerical pain rating scale anchored with 0= no pain to 100= the most intense pain sensation imaginable after exercise-induced muscle damage protocol From 0 to week 8
Secondary Swelling - Muscle thickness (mm or cm) Evaluated using musculoskeletal ultrasound From 0 to week 4
Secondary Swelling - overall thigh circumference (mm or cm) Evaluated using musculoskeletal ultrasound From 0 to week 4
Secondary Creatine kinase (UI/I) Blood marker analyzis After 4 weeks of supplementation
Secondary lactate dehydrogenase (U/L) Blood marker analyzis After 4 weeks of supplementation
Secondary Myoglobin (ug/l) Blood marker analyzis After 4 weeks of supplementation
Secondary Interleukin-6 (pg/ml) Blood marker analyzis - inflammation After 4 weeks of supplementation
Secondary Tumor necrosis factor-a (ug/ml) Blood marker analyzis - inflammation After 4 weeks of supplementation
Secondary C-reactive protein (mg/l) Blood marker analyzis - inflammation After 4 weeks of supplementation
Secondary Isometric Neuromuscular function Peak torque in Newton per meter (N/m) From 0 to week 4
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1